SCHEMBL2465241

SCHEMBL2465241

CC(C)n1cc(-c2ccc(Cl)c(C(F)(F)F)c2)cc(OCc2ccccc2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
COMT P21964 1/20 0.39
MCL1 Q07820 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
MAPK14 Q16539 4/20 0.38
KDM4E B2RXH2 1/20 0.37
RXRA P19793 2/20 0.37
RXRB P28702 2/20 0.37
RXRG P48443 2/20 0.37
S1PR1 P21453 1/20 0.36
MRGPRX4 Q96LA9 3/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471390 0.91 PPARG (0.40) MAOBPPARGPPARACOMTMCL1
SCHEMBL2466707 0.76 COMT (0.51) COMTKDM4E
SCHEMBL2462274 0.72 CCR5 (0.45) MAOBPDE4APDE4BPDE4CPDE4D
SCHEMBL22787011 0.66 KDM4E (0.42) PPARGPPARAKDM4ES1PR1MRGPRX4
SCHEMBL2469202 0.66 COMT (0.49) COMTKDM4E
SCHEMBL2538807 0.65 PPARG (0.41) PPARGPPARAS1PR1PTGER1
SCHEMBL31001965 0.65 USP1 (0.44) PDE4APDE4BPDE4CPDE4D
SCHEMBL2466390 0.65 BRD4 (0.52) MAPK14KDM4EMRGPRX4GAAPTGER1
SCHEMBL1041571 0.65 NOTUM (0.53)
SCHEMBL2538297 0.65 COMT (0.48) COMTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
EP-2542077-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT MAOB 7/4885PPARG 2229/4885PPARA 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.